Numerous studies have indicated that metastatic cells exhibit a CSC phenotype, characterized by markers such as ALDH+ and CD44+CD24− in breast cancer, CD26+ in colon cancer, and CD133+ in pancreatic cancer [56]. This evidence concerns the gene CD44 and familial pancreatic carcinoma.